jump to navigation

HE4–a novel promising serum marker in the diagnosis of ovarian carcinoma. February 18, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , , ,
add a comment

HE4–a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár ZNémeth MVleskó GKirály MHornyák LBösze P.

Source

2nd Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary. langmarzoltan@hotmail.com

Abstract

Biomarkers have a wide range of applications in the management of several cancers. To date serum markers have been the most extensively used biomarkers in everyday practice but few markers are elevated in preclinical or premalignant disease, limiting their importance for estimating risk or for screening. Human epididymis protein-4 (HE4) is a novel serum marker which is more sensitive in the prediction of risk of ovarian malignancy than CA125 alone in patients with a pelvic mass. HE4 in combination with CA125 appears to be an effective tool for the early detection of recurrence or monitoring the response to therapy. Risk of Ovarian Malignancy Algorithm, utilizing the dual marker combination of HE4 and CA125, can be used to stratify both postmenopausal and premenopausal women into high- and low-risk groups, allowing for an effective triage of women to appropriate institutions for their care. A review of HE4 and its feasibility as a novel diagnostic tool in the management of epithelial ovarian cancer is presented.

PubMed

Advertisements

A Surveillance Conundrum: A Case of 4 Distinct Primary Malignancies in a BRCA-1 Mutation Carrier. February 13, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , ,
add a comment

A Surveillance Conundrum: A Case of 4 Distinct Primary Malignancies in a BRCA-1 Mutation Carrier

Ricci SShafer ANerenstone SMandavilli SSorosky J.

University of Connecticut (S.R.), Farmington Hartford Hospital (A.S., S.N., S.M., J.S.), Hartford, CT.

Abstract 

Women with HBOC syndrome present a unique challenge to the oncology community, as will many genetic cancersyndromes yet to be discovered as genetic testing increases in availability. Issues of management and, most importantly, implication are yet to be elucidated. After a diagnosis of epithelial ovarian carcinoma lifelong follow-up is recommended. Given the high recurrence rate and dismal long term prognosis of advanced epithelial ovarian carcinoma this recommendation is more often than not moot. There are no clear guidelines or recommendations for surveillance designed for women with disease free survival greater than five years. This case presents a unique scenario of a woman with predictable disease that remains unpreventable.

PubMed